Literature DB >> 27640199

Jab1 promotes glioma cell proliferation by regulating Siah1/β-catenin pathway.

Yufu Zhu1,2, Zhichao Qiu1,3, Xiang Zhang1,3, Fengyuan Qian1,3, Bin Wang1,3, Lei Wang1,2, Hengliang Shi4,5, Rutong Yu6,7.   

Abstract

Jab1 (Jun activation domain-binding protein 1), also known as CSN5 (COP9 signalosome subunit 5), is frequently overexpressed in several cancer types. However, the biological functions and the molecular mechanisms of the Jab1 protein in human gliomas have not been investigated. In this study, we found that Jab1 protein was increasingly expressed in human glioma tissues comparing with normal brain tissues (Non-tumor). This suggested that Jab1 might be involved in the development of glioma. Thus, the role of Jab1 in glioma cell proliferation was investigated using Jab1 loss- and gain-of-function. The results showed that downregulation of Jab1 significantly inhibited glioma cell proliferation, while overexpression of Jab1 promoted it. Further investigation on molecular targets revealed that silencing of Jab1 obviously increased the p53 protein level thereby promoting the transcription of ubiquitin ligase Siah1 (Seven in absentia homolog 1), which aggravates the degradation of β-catenin. In contrast, overexpression of Jab1 had the opposite effect. Taken together, these findings suggest that Jab1 promotes glioma cell proliferation and increased expression of Jab1 in glioma patients may amplify β-catenin signaling to contribute to glioma cell proliferation.

Entities:  

Keywords:  Glioma; Jab1; P53; Siah1; β-Catenin

Mesh:

Substances:

Year:  2016        PMID: 27640199     DOI: 10.1007/s11060-016-2279-6

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  33 in total

Review 1.  Wnt/beta-catenin signaling in glioma.

Authors:  Kailiang Zhang; Junxia Zhang; Lei Han; Peiyu Pu; Chunsheng Kang
Journal:  J Neuroimmune Pharmacol       Date:  2012-03-28       Impact factor: 4.147

2.  Critical function for SIP, a ubiquitin E3 ligase component of the beta-catenin degradation pathway, for thymocyte development and G1 checkpoint.

Authors:  Toru Fukushima; Juan M Zapata; Netai C Singha; Michael Thomas; Christina L Kress; Maryla Krajewska; Stan Krajewski; Ze'ev Ronai; John C Reed; Shu-Ichi Matsuzawa
Journal:  Immunity       Date:  2006-01       Impact factor: 31.745

Review 3.  Current Understanding on EGFR and Wnt/β-Catenin Signaling in Glioma and Their Possible Crosstalk.

Authors:  Indranil Paul; Seemana Bhattacharya; Anirban Chatterjee; Mrinal K Ghosh
Journal:  Genes Cancer       Date:  2013-11

4.  The human F box protein beta-Trcp associates with the Cul1/Skp1 complex and regulates the stability of beta-catenin.

Authors:  E Latres; D S Chiaur; M Pagano
Journal:  Oncogene       Date:  1999-01-28       Impact factor: 9.867

5.  Roles for CSN5 in control of p53/MDM2 activities.

Authors:  Xiao-Chun Zhang; Jian Chen; Chun-Hui Su; Heng-Yin Yang; Mong-Hong Lee
Journal:  J Cell Biochem       Date:  2008-03-01       Impact factor: 4.429

6.  Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer.

Authors:  Francisco J Esteva; Aysegul A Sahin; George Z Rassidakis; Linda X H Yuan; Terry L Smith; Ying Yang; Michael Z Gilcrease; Massimo Cristofanilli; Rita Nahta; Lajos Pusztai; François-Xavier Claret
Journal:  Clin Cancer Res       Date:  2003-11-15       Impact factor: 12.531

7.  JAB1/CSN5: a new player in cell cycle control and cancer.

Authors:  Terry J Shackleford; Francois X Claret
Journal:  Cell Div       Date:  2010-10-18       Impact factor: 5.130

8.  Jun activation domain-binding protein 1 expression in breast cancer inversely correlates with the cell cycle inhibitor p27(Kip1).

Authors:  Maria A Kouvaraki; George Z Rassidakis; Ling Tian; Rakesh Kumar; Christos Kittas; François-Xavier Claret
Journal:  Cancer Res       Date:  2003-06-01       Impact factor: 12.701

9.  Expression of p27(Kip1) and c-Jun activation binding protein 1 are inversely correlated in systemic anaplastic large cell lymphoma.

Authors:  George Z Rassidakis; Francois-Xavier Claret; Raymond Lai; Qingxiu Zhang; Andreas H Sarris; Timothy J McDonnell; L Jeffrey Medeiros
Journal:  Clin Cancer Res       Date:  2003-03       Impact factor: 12.531

10.  The β-catenin E3 ubiquitin ligase SIAH-1 is regulated by CSN5/JAB1 in CRC cells.

Authors:  Sandra Jumpertz; Thomas Hennes; Yaw Asare; Jörg Vervoorts; Jürgen Bernhagen; Anke K Schütz
Journal:  Cell Signal       Date:  2014-05-29       Impact factor: 4.315

View more
  6 in total

1.  CSN5 Promotes Hepatocellular Carcinoma Progression by SCARA5 Inhibition Through Suppressing β-Catenin Ubiquitination.

Authors:  Hongliang Liu; Junwen Hu; Hua Pan; Dilai Luo; Mingwen Huang; Wei Xu
Journal:  Dig Dis Sci       Date:  2017-11-30       Impact factor: 3.199

Review 2.  Jab1/Cops5: a promising target for cancer diagnosis and therapy.

Authors:  Chunjue Yuan; Dong Wang; Guohong Liu; Yunbao Pan
Journal:  Int J Clin Oncol       Date:  2021-05-21       Impact factor: 3.402

3.  The critical role of EGF-β-catenin signaling in the epithelial-mesenchymal transition in human glioblastoma.

Authors:  Xingqiang Wang; Shanshi Wang; Xiaolong Li; Shigang Jin; Feng Xiong; Xin Wang
Journal:  Onco Targets Ther       Date:  2017-05-31       Impact factor: 4.147

4.  Loss of SH3GL2 promotes the migration and invasion behaviours of glioblastoma cells through activating the STAT3/MMP2 signalling.

Authors:  Yufu Zhu; Xiang Zhang; Lei Wang; Zhe Ji; Manyi Xie; Xinyu Zhou; Zhiyi Liu; Hengliang Shi; Rutong Yu
Journal:  J Cell Mol Med       Date:  2017-05-04       Impact factor: 5.310

5.  PHAP1 promotes glioma cell proliferation by regulating the Akt/p27/stathmin pathway.

Authors:  Manyi Xie; Zhe Ji; Yaxing Bao; Yufu Zhu; Yang Xu; Lei Wang; Shangfeng Gao; Zhiyi Liu; Zilu Tian; Qingming Meng; Hengliang Shi; Rutong Yu
Journal:  J Cell Mol Med       Date:  2018-04-18       Impact factor: 5.310

Review 6.  Targeting the COP9 signalosome for cancer therapy.

Authors:  Wenqi Du; Ruicheng Zhang; Bilal Muhammad; Dongsheng Pei
Journal:  Cancer Biol Med       Date:  2022-03-21       Impact factor: 5.347

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.